Harmony Biosciences Eyes Growth Beyond Wakix in 2025

Harmony Biosciences reported its Q4 and full-year earnings yesterday. Annual sales grew 23%, an impressive figure for a single orphan drug with a single indication (Wakix for narcolepsy). Management guided for approximately 18% growth in 2025 and expects this indication alone to surpass $1 billion in annual sales. The company’s long-term potential will become clearer this year, as its Phase 3 trial for ZYN002 is set to report initial data in Q3. ZYN002 was acquired through Harmony’s 2023 purchase of Zynerba, targeting Fragile X which represents a similar patient population to narcolepsy, with no currently approved treatments. A positive result could push Harmony’s stock closer to my fair value estimate of $73.

Watch List

WDAY -13.18%
VEEV 12.52%
PSTG -7.13%
INTU 14.19%
CMG 31.78%
RDDT 7.17%
NTNX 17.22%
CRWD 76.14%
SE 19.26%
SNOW 5.28%
APPF 6.95%

Buy List

PINS -37.54%
ASML -25.06%
SEMR -37.55%
TSM -43.44%
ZETA -32.89%
GOOG -51.47%
NYAX -30.39%
MSFT -31.81%
ODD -32.30%
ASR -26.98%
FLYW -44.52%
HRMY -60.41%
YOU -37.20%
ABNB -33.55%
MELI -26.26%
ADBE -45.26%

Hold List

VTEX -17.92%
CELH 49.08%
TOST 16.30%
CPNG -14.83%
HIMS -23.69%
PAYC -21.14%
MNDY 7.35%
GLBE -24.43%
ZS 23.06%
V -7.38%
ADSK -2.06%
NOW -1.85%
FTNT -4.90%
TEAM -8.65%